General Information of Drug (ID: DM64X25)

Drug Name
AMPE4L Drug Info
Synonyms Exendin4-Fc-Leptin; GLP1-Fc-Leptin; Exendin4-Fc-Leptin fusion protein (diabetes/obesity), Amprotein
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Investigative [1]
Cross-matching ID
TTD Drug ID
DM64X25

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Leptin receptor (LEPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metreleptin DM1NOEK Acquired generalized lipodystrophy Approved [3]
PEGylated leptin DMZ01PS Obesity 5B81 Investigative [2]
BL-5040 DMGULNZ Cachexia MG20 Investigative [2]
ANG-2004 DMK1IMC Obesity 5B81 Investigative [2]
AMPSL DMXRIUT Diabetic complication 5A2Y Investigative [2]
Leptin DM5LY1H Alzheimer disease 8A20 Investigative [2]
EDP-21 DMMN0GO Obesity 5B81 Investigative [2]
AMPPL DMVHOQE Diabetic complication 5A2Y Investigative [2]
PEG-LPA-2 DMY293M Solid tumour/cancer 2A00-2F9Z Investigative [2]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Semaglutide DMAGFOD Type-2 diabetes 5A11 Approved [4]
Liraglutide DM3FXPS Non-insulin dependent diabetes 5A11 Approved [5]
Exenatide DMYHBKN Inflammation 1A00-CA43.1 Approved [6]
Dulaglutide DMYXBV3 Type-2 diabetes 5A11 Approved [3]
Lixisenatide DM0QJDC Type-2 diabetes 5A11 Approved [7]
Pramlintide DM0EZ9Q Type-1/2 diabetes 5A10-5A11 Approved [5]
Albiglutide DM1JEGF Type-2 diabetes 5A11 Approved [7]
Tirzepatide DMQNMAT Type 2 diabetes 5A11 Approved [8]
Efpeglenatide DMKA2PI Type-2 diabetes 5A11 Phase 3 [9]
GLP-1 DMR6YH3 Diabetic complication 5A2Y Phase 3 [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon-like peptide 1 receptor (GLP1R) TTVIMDE GLP1R_HUMAN Modulator [1]
Leptin receptor (LEPR) TT0HD6V LEPR_HUMAN Modulator [2]

References

1 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249).
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9.
7 GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42.
8 Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)